JP2014518841A5 - - Google Patents

Download PDF

Info

Publication number
JP2014518841A5
JP2014518841A5 JP2013555576A JP2013555576A JP2014518841A5 JP 2014518841 A5 JP2014518841 A5 JP 2014518841A5 JP 2013555576 A JP2013555576 A JP 2013555576A JP 2013555576 A JP2013555576 A JP 2013555576A JP 2014518841 A5 JP2014518841 A5 JP 2014518841A5
Authority
JP
Japan
Prior art keywords
vaccine preparation
liposome
preparation according
pharmaceutically acceptable
liposomal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013555576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014518841A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/026385 external-priority patent/WO2012116225A2/en
Publication of JP2014518841A publication Critical patent/JP2014518841A/ja
Publication of JP2014518841A5 publication Critical patent/JP2014518841A5/ja
Pending legal-status Critical Current

Links

JP2013555576A 2011-02-24 2012-02-23 アジュバントを備えたmuc1ベースのグリコリポペプチドワクチン Pending JP2014518841A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446332P 2011-02-24 2011-02-24
US61/446,332 2011-02-24
US201161470449P 2011-03-31 2011-03-31
US61/470,449 2011-03-31
PCT/US2012/026385 WO2012116225A2 (en) 2011-02-24 2012-02-23 Muc1 based glycolipopeptide vaccine with adjuvant

Publications (2)

Publication Number Publication Date
JP2014518841A JP2014518841A (ja) 2014-08-07
JP2014518841A5 true JP2014518841A5 (OSRAM) 2015-03-12

Family

ID=46719120

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555576A Pending JP2014518841A (ja) 2011-02-24 2012-02-23 アジュバントを備えたmuc1ベースのグリコリポペプチドワクチン

Country Status (12)

Country Link
US (3) US8889616B2 (OSRAM)
EP (1) EP2678005A4 (OSRAM)
JP (1) JP2014518841A (OSRAM)
KR (1) KR20140023903A (OSRAM)
CN (2) CN103781469B (OSRAM)
AR (1) AR085490A1 (OSRAM)
AU (1) AU2012222188A1 (OSRAM)
BR (1) BR112013021779A2 (OSRAM)
CA (1) CA2825972A1 (OSRAM)
MX (1) MX2013009742A (OSRAM)
TW (1) TWI533881B (OSRAM)
WO (1) WO2012116225A2 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104211796A (zh) * 2013-11-09 2014-12-17 深圳市康尔诺生物技术有限公司 胰腺癌相关肽和热休克蛋白形成的复合物及其应用
WO2015126128A1 (en) * 2014-02-18 2015-08-27 Kolon Life Science, Inc. Agent for cancer therapy
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
CN106620682A (zh) * 2017-01-19 2017-05-10 华中师范大学 一种脂质体疫苗制剂及其用途和生产IgG抗体的方法
WO2019035605A2 (ko) * 2017-08-16 2019-02-21 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
KR102098097B1 (ko) 2017-08-16 2020-05-26 주식회사 차백신연구소 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도
CN109513002B (zh) * 2017-09-19 2024-02-20 台北医学大学 缓解发炎的tn疫苗及方法
WO2021110120A1 (zh) * 2019-12-04 2021-06-10 华中师范大学 一种抗肿瘤疫苗分子及其制备方法和应用
CN111760021B (zh) * 2020-05-18 2023-06-16 广州中医药大学(广州中医药研究院) 一种含有α-半乳糖神经酰胺类似物与糖抗原的缀合物及其制备方法和应用
CN111760020B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种缀合物及其制备方法和应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB699080A (en) 1950-05-31 1953-10-28 Ici Ltd Production of new esters of ortho-phosphoric acid and salts thereof
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5019383A (en) 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
DE3127503A1 (de) 1981-07-11 1983-02-17 Boehringer Mannheim Gmbh, 6800 Mannheim Neue phospholipide, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4464383A (en) 1981-11-24 1984-08-07 Itaru Yamamoto Immunomodulator containing trithiazole pentamethine cyanine derivative
ZA831547B (en) 1982-03-15 1984-10-31 New York Blood Center Inc Fatty acid carriers for synthetic vaccines
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4783402A (en) 1983-04-11 1988-11-08 Meito Sangyo Kabushiki Kaisha Production of primary or secondary alcohol derivatives of phospholipids by the enzymatic technique
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
GR860379B (en) 1985-02-22 1986-06-11 Akzo Nv Novel disaccharide and trisaccharide derivatives of the lipid a type
EP0219514A4 (en) 1985-04-03 1988-04-26 Wisconsin Alumni Res Found METHOD FOR PREVENTING DISEASES CAUSED BY GRAM-NEGATIVE ENDOTOXIN IN MAMMALY.
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
EP0203676B1 (en) 1985-04-19 1992-01-29 The Wistar Institute Of Anatomy And Biology Vaccine for generating an immunogenic t cell response protective against a virus
IT1213029B (it) 1986-01-30 1989-12-07 Bracco Ind Chimica Spa Chelati di ioni metallici paramagnetici.
JPS63139186A (ja) 1986-11-29 1988-06-10 Hidetoshi Tsuchida 三本鎖型リン脂質化合物およびその製造方法
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4868155A (en) 1987-10-05 1989-09-19 Merck & Co., Inc. Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5041427A (en) 1989-07-21 1991-08-20 Wisconsin Alumni Research Foundation Lipid A derivatives
JPH0655749B2 (ja) 1989-09-20 1994-07-27 日本たばこ産業株式会社 リピッドa単糖類縁体
US5993823A (en) 1990-12-18 1999-11-30 Institut Pasteur De Lille Cytotoxic T lymphocyte-inducing lipopeptides and methods of use
FR2670787B1 (fr) 1990-12-18 1995-06-23 Pasteur Institut Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins.
US5871746A (en) 1990-12-18 1999-02-16 Institut National De La Sainte Et De La Recherche Medicale (Inserm) Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines
ES2044781B1 (es) 1992-04-14 1994-10-01 Menarini Lab Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2
WO1993022343A1 (en) 1992-05-01 1993-11-11 The Rockfeller University Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom
FR2702306B1 (fr) 1993-03-05 1995-04-14 Alcatel Nv Procédé d'auto-alignement d'un contact métallique sur un substrat de matériau semi-conducteur.
IT1264690B1 (it) 1993-07-08 1996-10-04 Bracco Spa Compositi oligomeri iodurati e composizioni diagnostiche contenenti gli stessi
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
DE4408248A1 (de) 1994-03-11 1995-09-14 Hoechst Ag Physiologisch verträgliche und physiologisch abbaubare Kohlenhydrat-Mimetika, ein Verfahren zur Herstellung und ihre Verwendung
WO1995027505A1 (en) 1994-04-12 1995-10-19 Biomira, Inc. Cellular immune response-specific antigens and uses therefor
WO1995029927A2 (en) 1994-05-02 1995-11-09 Biomira, Inc. Process for preparation of glycosides of tumor-associated carbohydrate antigens
AU6260796A (en) 1995-06-07 1996-12-30 National Jewish Center For Immunology And Respiratory Medicine Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof
AUPN568095A0 (en) 1995-09-27 1995-10-26 Austin Research Institute, The Anti-Galalpha(1,3)Gal antibody binding peptides
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
WO1997034921A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Conjugated mucin peptide vaccines
WO1997038010A2 (en) 1996-04-11 1997-10-16 The University Of British Columbia Fusogenic liposomes
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
ATE394474T1 (de) 1997-05-08 2008-05-15 Biomira Inc Verfahren zur gewinnung von aktivierten t-zellen und mit antigen inkubierten antigenpräsentierenden zellen
FR2774687B1 (fr) 1998-02-06 2002-03-22 Inst Nat Sante Rech Med Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
WO1999040881A2 (en) * 1998-02-13 1999-08-19 Gunther Bastert Specific antibodies against mammary tumor-associated mucin, method for production and use
US6043390A (en) 1998-04-03 2000-03-28 The Regents Of The University Of California Pentaerythritol lipid derivatives and nucleic-acid complexes
FR2776926B1 (fr) 1998-04-07 2003-10-24 Inst Nat Sante Rech Med Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination
US20020051813A1 (en) 1999-01-15 2002-05-02 Lawrence Boni Lipomatrix preparation
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Muc−1抗原に対する治療用抗体およびその使用方法
DE60030450T2 (de) 1999-09-08 2007-08-30 Transgene S.A. Von MUC-1 abgeleitete Peptide
EP1232168B1 (en) 1999-11-15 2011-08-03 Oncothyreon Inc. Synthetic lipid-a analogs and uses thereof
US6699846B2 (en) 2000-03-17 2004-03-02 Corixa Corporation Mono- and disaccharides for the treatment of nitric oxide related disorders
AU4871001A (en) 2000-03-24 2001-10-03 Biomira Inc Lipopeptide adjuvants
ES2164013B1 (es) 2000-04-14 2003-06-16 Consejo Superior Investigacion Glicosidos de n-acetil-6-o-(2,2-bis(hidroximetil)-3-hidroxipropil)-d-glucosamina, procedimiento de obtencion y uso en el tratamiento de tumores cerebrales.
EP1182210A1 (en) 2000-08-17 2002-02-27 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Epitopes of tumor-associated MUC1 antigen
CN1455680A (zh) * 2000-09-11 2003-11-12 达纳-法伯癌症协会有限公司 Muc1胞外域和癌症治疗组合物及方法
EP1343476B1 (en) 2000-12-01 2008-05-28 Biomira Inc. Preparation of large liposomes by infusion into peg
US8198400B2 (en) 2001-03-27 2012-06-12 Oncothyreon, Inc. Vaccine for modulating between T1 and T2 immune responses
EP1474432A1 (en) 2002-02-04 2004-11-10 Biomira Inc. Immunostimulatory, covalently lipidated oligonucleotides
WO2003089574A2 (en) * 2002-04-15 2003-10-30 Biomira, Inc. Synthetic glyco-lipo-peptides as vaccines
EP1549322B1 (en) 2002-05-09 2010-02-17 Oncothyreon Inc. Lipid a and other carbohydrate ligand analogs
GB0212046D0 (en) * 2002-05-24 2002-07-03 Glaxo Group Ltd Vaccines
US20030235610A1 (en) 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US9198645B2 (en) 2003-11-26 2015-12-01 The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology Controlled vesicle self-assembly in continuous two phase flow microfluidic channels
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1896051B1 (en) 2005-06-28 2014-10-15 Oncothyreon Inc. Method of treating patients with a mucinous glycoprotein (muc-1) vaccine
JP5126874B2 (ja) 2007-05-21 2013-01-23 国立大学法人神戸大学 リポソーム製剤の製造方法
EA020604B1 (ru) 2008-12-17 2014-12-30 Онкотиреон, Инк. Композиция, содержащая липосомы малого размера, и способ ее получения

Similar Documents

Publication Publication Date Title
JP2014518841A5 (OSRAM)
JP2013534248A5 (OSRAM)
JP2013519645A5 (OSRAM)
JP2013545785A5 (OSRAM)
JP2017522277A5 (OSRAM)
JP2015024998A5 (OSRAM)
JP2012072150A5 (OSRAM)
JP2014500861A5 (OSRAM)
JP2015512946A5 (OSRAM)
JP2014508753A5 (OSRAM)
JP2016513638A5 (OSRAM)
JP2013510120A5 (OSRAM)
JP2018065821A5 (OSRAM)
JP2011504486A5 (OSRAM)
JP2016518328A5 (OSRAM)
JP2017537066A5 (OSRAM)
JP2013542247A5 (OSRAM)
WO2007095976A3 (de) Adjuvanz in form einer lipid-modifizierten nukleinsäure
JP2009541236A5 (OSRAM)
JP2009191078A5 (OSRAM)
JP2019518739A5 (OSRAM)
JP2012532134A5 (OSRAM)
JP2012532883A5 (OSRAM)
JP2015523546A5 (OSRAM)
JP2013542981A5 (OSRAM)